- ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!
The weak companies could be clobbered.
Regulators say company squelched competing drug for infant seizures.
Drugmaker faced antitrust charges over 2013 Synacthen purchase.
The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.